Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew Posard sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $96.43, for a total value of $482,150.00. Following the completion of the transaction, the director owned 48,609 shares of the company’s stock, valued at $4,687,365.87. This trade represents a 9.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Halozyme Therapeutics Stock Performance
Shares of HALO opened at $93.04 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The stock has a 50-day moving average of $113.53 and a two-hundred day moving average of $85.96. The stock has a market cap of $10.61 billion, a P/E ratio of 23.67, a P/E/G ratio of 0.36 and a beta of 0.92. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The business had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. During the same period in the prior year, the company earned $1.72 earnings per share. The company’s revenue was up 39.1% on a year-over-year basis. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. Morgan Stanley lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $105.00 to $109.00 in a research report on Wednesday, November 11th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Monday. Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a report on Friday, November 6th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 3rd. Finally, Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 11th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $108.18.
Check Out Our Latest Report on HALO
Institutional Trading of Halozyme Therapeutics
A number of hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC raised its position in Halozyme Therapeutics by 47.9% during the third quarter. Kestra Advisory Services LLC now owns 14,793 shares of the biopharmaceutical company’s stock valued at $1,633,000 after acquiring an additional 4,788 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $776,000. Zacks Investment Management boosted its position in Halozyme Therapeutics by 2.6% in the 3rd quarter. Zacks Investment Management now owns 33,464 shares of the biopharmaceutical company’s stock worth $3,694,000 after purchasing an additional 837 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in shares of Halozyme Therapeutics by 15.2% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 4,643 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 612 shares during the period. Finally, Groupama Asset Managment acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $2,630,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Key Stories Impacting Halozyme Therapeutics
These are some of the HALO stories that stood out recently:
- Neutral Sentiment: Halozyme said it will continue pursuing its permanent patent case against Merck after the court reversed the preliminary injunction. That case remains unresolved. Article: Halozyme to pursue permanent patent case against Merck
- Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering Keytruda SC in Germany. The ruling removes that immediate barrier to the product’s distribution and raises concern about Halozyme’s ability to enforce its patent there while the broader case proceeds. Article: Halozyme provides update on German preliminary injunction hearing
- Negative Sentiment: Broader market weakness added pressure: the S&P 500 and healthcare sector were also lower during the session. Article: Halozyme stock slides as European patent fight with Merck spurs pressure
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Recommended Stories
- Five stocks we like better than Halozyme Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
